4.8 Article

The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD

期刊

NATURE COMMUNICATIONS
卷 11, 期 1, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-019-14238-3

关键词

-

资金

  1. TB Structural Genomics Consortium [P01AI095208]
  2. NIAID, NIH [A-0015]
  3. Welch Foundation
  4. DOE Office of Science by Argonne National Laboratory
  5. U.S. Department of Energy, Office of Biological and Environmental Research [DE-AC02-06CH11357]

向作者/读者索取更多资源

Pyrazinamide has been a mainstay in the multidrug regimens used to treat tuberculosis. It is active against the persistent, non-replicating mycobacteria responsible for the protracted therapy required to cure tuberculosis. Pyrazinamide is a pro-drug that is converted into pyrazinoic acid (POA) by pyrazinamidase, however, the exact target of the drug has been difficult to determine. Here we show the enzyme PanD binds POA in its active site in a manner consistent with competitive inhibition. The active site is not directly accessible to the inhibitor, suggesting the protein must undergo a conformational change to bind the inhibitor. This is consistent with the slow binding kinetics we determined for POA. Drug-resistant mutations cluster near loops that lay on top of the active site. These resistant mutants show reduced affinity and residence time of POA consistent with a model where resistance occurs by destabilizing the closed conformation of the active site. The important tuberculosis drug pyrazinamide (PZA) is converted to its active form pyrazinoic acid (POA) in Mycobacterium tuberculosis (Mtb). Here the authors identify the pantothenate biosynthesis pathway enzyme aspartate decarboxylase (PanD) as the target of PZA and determine the POA bound Mtb PanD crystal structure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据